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Abstract
Nearly half of all human proteins are acetylated at their N-termini by the NatA N-terminal acetyltransferase complex.
NAA10 is evolutionarily conserved as the catalytic subunit of NatA in complex with NAA15, but may also have NatA-
independent functions. Several NAA10 variants are associated with genetic disorders. The phenotypic spectrum includes
developmental delay, intellectual disability, and cardiac abnormalities. Here, we have identified the previously undescribed
NAA10 c.303C>A and c.303C>G p.(N101K) variants in two unrelated girls. These girls have developmental delay, but they
both also display hemihypertrophy a feature normally not observed or registered among these cases. Functional studies
revealed that NAA10 p.(N101K) is completely impaired in its ability to bind NAA15 and to form an enzymatically active
NatA complex. In contrast, the integrity of NAA10 p.(N101K) as a monomeric acetyltransferase is intact. Thus, this NAA10
variant may represent the best example of the impact of NatA mediated N-terminal acetylation, isolated from other potential
NAA10-mediated cellular functions and may provide important insights into the phenotypes observed in individuals
expressing pathogenic NAA10 variants.
Introduction
N-terminal (Nt) acetylation is a ubiquitous protein mod-
ification that pertains to ~80% of the human proteome [1].
Eight N-terminal acetyltransferases (NATs), named NatA to
NatH, have been identified to date, whereof all except NatG
are expressed in humans [2]. The cellular roles of Nt-
acetylation are manifold and not fully understood, but some
reported functions include regulation of protein complex
formation, folding, degradation, subcellular localization,
and membrane interactions [2–6]. NatA is the major NAT
accounting for almost half of the Nt-acetylome due to its
broad substrate specificity [1]. NatA is comprised of the
catalytic subunit NAA10 and its binding partners NAA15,
HYPK, and NAA50 (NatE) [7–11]. Binding of NAA10
to NAA15 ensures ribosomal anchoring and alters the
substrate specificity of NAA10 to NatA specific substrates
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including small, polar amino acids [10, 12–14]. Moreover,
NAA10 also exists as a monomer in the cell and is sug-
gested to independently act as a lysine acetyltransferase
(KAT) and noncatalytic regulator of diverse target proteins
[2, 15–19]. NAA10 is an essential gene and loss of function
is lethal in model organisms such as T. brucei, D. rerio, D.
melanogaster, and C. elegans [20–23]. In humans, NAA10
has been implicated in cancer signalling pathways both as a
tumour suppressor and an oncoprotein, and is believed to
have a regulatory role in cell proliferation and survival [24].
Furthermore, NAA10 missense variants have in recent years
emerged as causative of genetic disease, collectively known
as NAA10-related syndrome [25]. This X-linked condition is
associated with a broad spectrum of phenotypes including
developmental delay (DD), intellectual disability (ID), and
cardiac abnormalities [26]. This was first discovered in
2011, when a NAA10 c.109T>C p.(S37P) variant was
detected as the cause of Ogden syndrome (OMIM #300855)
[27]. Affected boys had severe global developmental delay,
craniofacial abnormalities, hypotonia and cardiac arrhyth-
mia, and died within 16 months of age. Studies revealed that
the NAA10 c.109T>C p.(S37P) variant led to impaired NatA
complex formation as well as decreased Nt-acetylation of
NatA substrates in patient cells [27–29]. A NAA10 splice-
site variant c.471+2T>A was identified as one cause of of
Lenz Microphthalmia Syndrome (OMIM #309800) in four
males presented with anophthalmia, ID, developmental
delay, and other malformations [30]. Popp et al. reported
a boy and a girl carrying the NAA10 variants c.319G>T
p.(V107F), and c.346C>T p.(R116W) respectively, with
severe ID, postnatal growth retardation, hypotonia, and
behavioural anomalies [31]. Casey et al. described two
brothers with ID, facial dysmorphism, scoliosis, and long
QT who harboured a c.128A>C p.(Y43S) variant inherited
from their mildly affected mother [32]. A recurrent mis-
sense variant, c.247C>T p.(R83C), has been identified in
seven females with ID and developmental delay [26]. In all
of these cases, this variant arose de novo, except for one
case of maternal inheritance in which the female also had an
affected brother who suffered a neonatal death. Further-
more, a missense variant affecting the same amino acid,
c.248G>A p.(R83H), was recently detected in two unrelated
boys with ID, developmental delay, and hypertrophic car-
diomyopathy [33]. Missense variants affecting Arg83
are believed to impair Ac-CoA binding and cause reduced
Nt-acetylation, resulting in the observed phenotypes
[26, 33]. Three variants, c.384T>A p.(F128I), c.382T>A
p.(F128L), and c.332T>G p.(V111G), have been reported
in four females with ID and functional studies showed
reduced Nt-acetylation caused by destabilisation of the
NAA10 structure [26, 34]. Another three males displaying
global DD, ID, and hypertrophic cardiomyopathy were
found to harbour a c.215T>C p.(I72T) variant [35]. Finally,
a recent international cohort presented 23 individuals with
ten different NAA10 variants [36]. Three of the variants
have previously been described including the recurrent
c.247C>T p.(R83C) variant, which in this study was found
in 11 more individuals. Novel NAA10 variants presented in
the cohort include c.29A>G p.(D10G), c.32T>G p.(L11R),
c.259G>T p.(A87S), c.311C>A p.(A104D), c.361C>G
p.(L121V), c.440T>C p.(M147T), and a frameshift variant
c.455_458del p.(Thr152fs) [36]. An overview of previously
described NAA10 variants is available in the Supplementary
information (Supplementary Table S1). As the clinical
spectrum associated with NAA10 deficiency is expanding
and new variants continue to emerge, there is currently
limited overall understanding of the underlying disease
mechanisms involved. Here we present two unrelated
females harbouring two different genetic NAA10 variants,
c.303C>A and c.303C>G, which both encode the same
NAA10 p.(N101K) variant. The females display overlapping
phenotypes including developmental delay, dysmorphic
features, hemihypertrophy, and hearing loss. Functional
studies suggest that this variant only impairs NatA activity
and not monomeric NAA10 function.
Materials and methods
Construction of plasmid
A plasmid encoding the NM_003491.3 NAA10 c.303C>A
p.(N101K) missense variant was generated using the Q5
Site Directed Mutagenesis Kit (New England Biolabs, MA,
USA) and pcDNA3.1/NAA10-V5-His vector as template.
The forward and reverse primers used were 5′-TGATAG
AGAAATTCAATGCCAAATATGTCTCCC-3′ and 5′-TG
GCTCGAGAGGCCTGGT-3′ respectively, with an annea-
ling temperature of 68 °C. The variant was confirmed by
sequencing.
Immunoprecipitation and Western blot analysis
Transfection of HeLa cells (ATTC, CCL-2) was performed
using X-tremeGENE 9 DNA Transfection Reagent (Roche,
Basel, Switzerland) as described in the instruction manual.
The amount of DNA used for the different vectors were
as follows: 10–12 µg of pcDNA3.1/NAA10-N101K-V5,
2.5–4 µg of pcDNA3.1/NAA10-WT-V5, 7.5–10 µg of
pcDNA3.1/NAA15-myc-His or 10 µg of pcDNA3.1/LacZ-
V5 (control-vector). 5–10 µg of empty pcDNA3.1/V5
plasmid was co-transfected with pcDNA3.1/NAA10-WT-V5
to attain equal amounts of DNA in the transfection mix.
Transfected cells were harvested after two days of growth
and lysed in 0.5–1 ml IPH lysis buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1×
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complete EDTA-free protease inhibitor cocktail) for 15 min
at 4 °C on a rotator. The cell lysates were centrifuged
at 17,000 × g and 4 °C for 5 min and the supernatants col-
lected. For immunoprecipitation (IP), the lysates were
incubated with 1.5–4 µg of V5-tag antibody (Invitrogen
#R960-25, CA, USA) or 3 µg NAA15 antibody [7]
(BioGenes, Berlin, Germany) at 4 °C for 2 h on a rotator
before adding 20–40 µl of washed Dynabeads Protein G
(Invitrogen, CA, USA). After overnight incubation, the
beads were washed three times in IPH lysis buffer. Then,
the beads were either resuspended in 90 µl acetylation
buffer (50 mM Tris-HCl pH 8.5, 1 mM EDTA, 10%
Glycerol) to be used in a Nt-acetylation assay or in
×1 sample buffer to be analysed by Western blot. Samples
were analysed using standard Western blot technique, and
immunoblots were probed with V5-tag antibody (1:5000
dilution, Invitrogen #R960-25), NAA15 antibody (1:2000
dilution, BioGenes (named anti-NATH) [7]) and myc-tag
antibody (1:2000 dilution, Invitrogen #R950-25). The
ChemiDoc XRS+ system (Bio-Rad, CA, USA) coupled
with Imagelab Software (Bio-Rad, CA, USA) was used to
image and quantify protein bands.
[14C]-Ac-CoA-based Nt-acetylation assay
To compare the intrinsic enzyme activity of V5-
immunoprecipitated NAA10 WT-V5 and NAA10 N101K-
V5, Nt-acetylation assays were performed as described
previously [37]. In short, we used triplicate reactions con-
taining 10 µl immunoprecipitated enzyme, 50 µM [14C]-
Ac-CoA (PerkinElmer, MA, USA), 200 µM oligopeptide
SESS24 (SESSSKSRWGRPVGRRRRPVRVYP) or EEEI24
(EEEIAALRWGRPVGRRRRPVRVYP) (BioGenes, Ber-
lin, Germany), and acetylation buffer with a total volume of
25 µl. Oligopeptide was omitted in negative control reac-
tions. Reactions were run for 30 min at 37 °C and 1400 rpm
in a thermomixer. Afterwards, 23 µl of the supernatant was
transferred onto P81 phosphocellulose filter discs (Milli-
pore, MA, USA) which were subsequently washed three
times in 10 mM HEPES buffer (pH 7.4) and air dried.
Finally, the filter discs were submerged in 5 ml Ultima Gold
F scintillation mixture (PerkinElmer, MA, USA) and the Nt-
acetylated product was measured by a TriCarb 2900TR
Liquid Scintillation Analyzer (PerkinElmer, MA, USA).
Multiple sequence alignment and structural
modelling
A multiple sequence alignment was generated using Clustal
Omega [38] and illustrated by ESPript 3.0 [39]. The protein
sequences are available in Supplementary Table S2. The
structural analysis of human NatA (PDB ID: 6C9M) [40]
was performed using PyMOL [41]. Acetyl-CoA was
inserted in the hNatA structure through superimposition
with the S. pombe NAA10 structure (PDB ID: 4KVX) [13]
solved with acetyl-CoA bound.
Exome sequencing
The family 1 proband participated in a translational research
study (CAUSES Study) with institutional ethical approval
from the University of British Columbia [H15-00092]. The
family 2 proband participated in a rare diseases registry,
with institutional ethical approval from Fundación Valle del
Lili [01504]. Genomic DNA was isolated using standard
techniques from the peripheral blood of family trios (pro-
band, mother, and father). Each member of the trio had
hybridization-based exome capture sequencing performed
on an Illumina platform at Ambry Genetics (Aliso Viejo,
CA, USA) for family 1 and at Agilent Technologies (Santa
Clara, CA, USA) for family 2. A bioinformatics pipeline
identified functional rare variants that were consistent with
Mendelian patterns of inheritance as determined with the
trio family structure. Sequencing reads were aligned to a
reference human genome based on hg19 (ftp://hgdownload.
cse.ucsc.edu/goldenPath/hg19/) using Bowtie2–2.2.6 [42].
Once mapped, Picard-tools-1.139 (http://broadinstitute.
github.io/picard/) marked duplicate reads, and GATK-3.5-
0 was applied for indel realignment [43]. Samtools-0.1.19
and bcftools-0.2 were used to call and filter single-
nucleotide variants and indels [44]. SnpEff-4.1L [45]
annotated Ensembl 75 transcripts [46] and identified func-
tional variants, which were then annotated and filtered
against in-house and public databases: dbSNP 144 [47],
1000G [48], ESP6500SI-V2 [49], and ExAC v0.3 [50]. A
list of rare functional variants consistent with Mendelian
inheritance patterns was annotated and prioritised using
custom scripts and ANNOVAR 2015–06–17 [51] with
diagnostically relevant information (e.g., OMIM [52],
ClinVar [53], DECIPHER [54], LOVD 3.0 [55], NCBI gene
summaries (ftp://ftp.ncbi.nlm.nih.gov/refseq/H_sapiens/Ref
SeqGene/), RVIS [56], and dbNSFP v3.0 [57]). Functional
studies were undertaken after both clinical teams indepen-
dently approached the functional analysis lab at the Uni-
versity of Bergen. The NAA10 c.303C>G p.(N101K) and
NAA10 c.303C>A p.(N101K) variants were submitted to
ClinVar (SCV001193440 and SCV001335306).
Results
Clinical report: individual 1
Individual 1 is a female with a de novo NAA10 c.303C>A
p.(N101K) (NG_031987.1 (NM_003491.3):c.303C>A, hg19:
g.153197807G>T) variant who was referred to genetic
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evaluation at 5 years of age for global developmental delay,
dysmorphic features, and left sided hemihypertrophy
(Fig. 1a–c). She is the first child of her non-consanguineous
parents and has a healthy younger sibling. The pregnancy was
complicated by light per vaginam bleeding in the second
trimester. She was born with a birth weight of 3.15 kg.
Asymmetry of her body was noted in the neonatal period with
the entire left side being larger than the right. She fed very
slowly initially but did gain weight. Left sided hip subluxation
was noted and surgically corrected with good result.
She failed her initial hearing test and on follow up was
noted to have mild bilateral sensorineural hearing loss
and wears hearing aids. Ophthalmic assessment revealed
right posterior embryotoxon and anomalous optic nerves.
An MRI of the brain was performed abroad and thought to
be normal and we are awaiting repeat locally. Parents note
delays in all areas of development. She has been diagnosed
with moderate intellectual disability. Chromosome micro-
array, cardiac echo, and renal ultrasound were all normal.
She did not meet the clinical criteria for Beckwith–
Wiedemann syndrome (BWS) in that there was no evidence
of neonatal hypoglycaemia, birthweight was on the 25th
centile and she had no dysmorphic features of this condi-
tion. In addition, molecular testing for BWS returned
negative. Renal ultrasound surveillance has remained nor-
mal. At the time of our first meeting she was noted to have
significant micrognathia, short palpebral fissures and simple
cup shaped ears (Fig. 1b). The hemihypertrophy is growing
along with her, no sandal gap, thickening of the sole of the
foot, vascular abnormalities, and lipomata. The left foot
is 1.5 cm longer than the right foot (Fig. 1c). No other
diagnosis for her asymmetry was diagnosed clinically. She
has continued to grow along the 3rd centile for height and
weight, and OFC has been −2SD below the mean. Exome
sequencing identified a de novo variant of uncertain sig-
nificance (VUS) in the NAA10 gene: NAA10 c.303C>A
p.(N101K).
Clinical report: individual 2
Individual 2 with a de novo NAA10 c.303C>G p.(N101K)
(NG_031987.1 (NM_003491.3):c.303C>G, hg19:g.153197
807G>C) variant is a 4-year-old female referred to genetics
evaluation for global developmental delay, dysmorphism,
short stature, and right sided hemihypertrophy (Fig. 1d–f).
Proband is the first child of non-consanguineous healthy
parents of Colombian descent. She has one healthy sibling
and no family history of congenital anomalies or intellectual
disability. Mother was a healthy 29-year-old G2P1. Preg-
nancy was complicated by intrauterine growth restriction
and prenatal imaging concerning for Dandy–Walker mal-
formation. Individual was born at 36 weeks of gestational
age via c-section. Birth weight was 1.53 kg (<3rd centile),
length 40 cm (<3rd centile), and head circumference 29.5
Fig. 1 Patient photographs.
Photographs of individual




2 showing dysmorphology (d),
hemihypertrophy (R>L) (e) and
broad hallux (f).
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cm (<3rd centile). The individual had poor respiratory effort
requiring admission to the neonatal intensive care unit for
10 days. No additional hospitalizations or respiratory con-
cerns. Hearing evaluation revealed severe bilateral hearing
loss. Developmental history is remarkable for delayed
walking (age 3) and speech (first words at age 4). BWS
testing has not been performed as she does not meet the
clinical criteria. Dysmorphology evaluation at age 4 years
was remarkable for broad forehead, arched eyebrows, eso-
tropia, broad columella, and full lips. She had joint hyper-
mobility, short fingers with trident appearance, broad
hallux, and the right foot was longer than the left foot (0.8
cm at last evaluation) (Fig. 1e, f). Growth parameters
measured at last evaluation were weight was 17.15 kg (50th
centile, 0.1 SD), height 90.8 cm (<3rd centile, −3.19 SD),
and head circumference 49.5 cm (30th centile, 0.6 SD).
Imaging evaluation included brain MRI that confirmed
Dandy–Walker malformation and agenesis of the corpus
callosum. Echocardiogram and renal ultrasound were nor-
mal. The girl has stereotypies and severe aggressive beha-
viour including biting and kicking caregivers. At last visit
she was communicating using few words, her walk was
more stable, and family reported that the she needed help
with feeding, dressing, and was also not yet potty trained.
Genetic workup included normal chromosomes (46, XX)
and chromosomal microarray. Exome trio analysis was
performed and this identified a de novo VUS in the NAA10
gene: NAA10 c.303C>G p.(N101K). This variant was not
found in GnomAD exomes or genomes.
Functional assessment of NAA10 p.(N101K)
In order to investigate the catalytic activity of NAA10
N101K in comparison to NAA10 WT, V5-tagged NAA10
was overexpressed in HeLa cells and immunoprecipitated
using V5-tag antibody. The immunoprecipitates were used
in Nt-acetylation assays and the amount of NAA10-V5 and
co-immunoprecipitated NAA15 in the samples was deter-
mined by Western blot analysis (Fig. 2a). Interestingly,
there was not detected any co-immunoprecipitation of
NAA15 with the NAA10 N101K-V5 variant in contrast to
NAA10 WT-V5, indicating that the missense variant hin-
ders NatA complex formation. This observation was further
supported by a reciprocal IP using NAA15 antibody, where
only NAA10 WT-V5 co-immunoprecipitated with NAA15
(Fig. 2b). To exclude the possibility that NAA10 N101K-
V5 does not bind NAA15 because it cannot compete with
endogenous NAA10, we also simultaneously overexpressed
both NAA15-myc and NAA10-V5 and performed V5-IP
(Fig. S1). In agreement with the other IP experiments,
NAA15-myc did not co-immunoprecipitate with NAA10
N101K-V5 while NAA15-myc readily formed a complex
with NAA10 WT-V5.
The catalytic activity of NAA10 N101K-V5 and NAA10
WT-V5 was tested in an Nt-acetylation assay using the
oligopeptides SESS24 and EEEI24, representing a NatA
substrate and an in vitro monomeric NAA10 substrate,
respectively (Fig. 2c, Supplementary Table S3). Since
SESS24 is a NatA substrate, the catalytic activity toward this
substrate was normalised to the amount of NAA15 in the
immunoprecipitate, while the catalytic activity toward
EEEI24 was normalised to the amount of NAA10-V5. As
shown in Fig. 2c, NAA10 N101K-V5 has an abolished
NatA activity toward SESS24 which is in accordance with
the lack of co-immunoprecipitated NAA15 seen in the
Western blot analysis (Fig. 2a). In contrast, the catalytic
activity of NAA10 N101K-V5 toward EEEI24 was equal to
Fig. 2 NatA complex formation and catalytic activity of immuno-
precipitated NAA10 WT-V5 and NAA10 N101K-V5. NAA10
WT-V5 and NAA10 N101K-V5 were overexpressed in HeLa cells,
immunoprecipitated by V5-tag antibody (a) or NAA15 antibody (b)
and analysed by Western blotting. Densitometry analysis was per-
formed to quantify NAA10-V5 and NAA15 bands. c Nt-acetylation
assay displaying catalytic activity of immunoprecipitated NAA10 WT-
V5 and NAA10 N101K-V5. The measured catalytic activity toward
NatA substrate SESS24 and monomeric NAA10 substrate EEEI24 was
normalised to the amount of immunoprecipitated NAA15 and NAA10-
V5, respectively. Reaction mixtures either with immunoprecipitated β-
gal-V5 or without peptide were used as negative controls to account
for background signal. The IP and activity measurements were per-
formed in three independent setups, each with three technical repli-
cates per assay. One representative setup is shown.
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that of NAA10 WT-V5, suggesting that the monomeric
NAA10 catalytic function is not affected by the variant.
Taken together, these results indicate that the NAA10
c.303C>A and c.303C>G p.(N101K) variants are incapable
of binding to NAA15, which results in abolished NatA
catalytic activity, while monomeric NAA10 c.303C>A and
c.303C>G p.(N101K) catalytic activity remains intact.
Multiple sequence alignment and structural analysis
NAA10 adapts the characteristic GCN5-related N-acetyl-
transfererase (GNAT) fold common for many acetyl-
transferases. The GNAT fold is a highly conserved structural
domain comprising an Ac-CoA binding region, six or seven
β-strands and four α-helices [58]. Asn101 is located within
the conserved GNAT fold of NAA10, but a multiple sequence
alignment of NAA10 orthologues revealed that the Asn101
residue itself is only semi-conserved across the species pre-
sented in Fig. 3a. Structural investigations of the hNatA
structure (PDB ID: 6C9M) [40] showed that Asn101 is
located in the α3 helix in close proximity to NAA15, with its
polar side chain protruding toward the α12-loop-α13 segment
of NAA15 (Fig. 3b). A structural analysis performed in
PyMOL did not show any predicted interactions between the
side chain of Asn101 and surrounding amino acids in neither
NAA15 nor NAA10 (Fig. 3b).
Discussion
In recent years, an increasing number of NAA10 variants
have been identified in both male and female individuals
with varying degrees of phenotype severity [25]. In this
study, we report two novel de novo genetic variants NAA10
c.303C>A and c.303C>G p.(N101K) in two unrelated
females with overlapping phenotypes including develop-
mental delay, hemihypertrophy, hearing loss, and dys-
morphic features. The significantly impaired function of
NAA10 p.(N101K) defined in our biochemical assays
combined with the other features clearly classify these
variants as pathogenic (class 5) according to ACMG
guidelines [59]. X-inactivation patterns have previously
been suggested to influence phenotype severity in female
carriers of NAA10 variants [26]. Due to the severe func-
tional impairment of NatA activity of NAA10 p.(N101K),
and the necessity of NatA mediated Nt-acetylation for life in
multicellular eukaryotes [20–23, 60], we speculate that the
females harbouring the NAA10 c.303C>A and c.303C>G
Fig. 3 NAA10 multiple sequence alignment and NatA structural
analysis. a Multiple sequence alignment of NAA10 orthologues from
human, mouse, rat, zebrafish, frog, and yeast. Secondary structure was
determined from hNatA structure (PDB ID: 6C9M) [40] and amino
acid conservation is indicated by red colour. b Human NatA structure
(PDB ID: 6C9M) [40] with the auxiliary subunit NAA15 (grey), the
catalytic subunit NAA10 (green) and Ac-CoA and IP6 shown as
orange and blue sticks, respectively. The structure was superimposed
on Ac-CoA from the S. pombe NAA10 structure (PDB ID: 4KVX)
[13]. The variant site Asn101 is coloured red. Close-up of
Asn101 shows that it is located in NAA10 α3 helix with its side chain
protruding toward NAA15.
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p.(N101K) variants have skewed X-inactivation. However,
this has not been experimentally tested.
Most of the previously characterised NAA10 missense
variants have been shown to reduce monomeric NAA10
NAT-activity in vitro after being ectopically expressed and
purified [26, 27, 31–34]. Interestingly, a recent cohort study
demonstrated that ectopically purified NAA10 variants
displayed different effects on catalytic activity depending
on whether it was present in the core NatA complex
(NAA10-NAA15) or the trimeric NatA/HYPK complex
(HYPK is a stable interactor of the NatA complex in vivo)
[36]. For this reason, we believe that testing NAT-activity
using immunoprecipitated NAA10 or NatA complexes from
human cells, as performed herein, presents a more reliable
method for predicting the catalytic consequences of NAA10
variants in vivo. Due to the unresolved biochemical com-
plexity of NAA10 and the plethora of downstream cellular
phenotypes [2], a standardised assay to comparatively
assess the full impact of a larger number of NAA10 variants
is not currently available.
Both IP of NAA10 N101K-V5 and reciprocal IP of
NAA15 showed that NAA10 N101K-V5 does not bind
NAA15 (Fig. 2a, b). Since this could be due to an inability
of NAA10 N101K-V5 to compete with endogenous
NAA10, a scenario avoided in patient cells expressing
NAA10 p.(N101K), NatA complex formation was also
assessed in cells overexpressing both NAA10-V5 and
NAA15-myc. Interestingly, even with an excess of NAA15-
myc, NAA10 N101K-V5 was not able to bind NAA15
(Fig. S1). This strongly suggests that the missense variant
completely eradicates NatA complex formation.
The in vitro Nt-acetylation activity assay displayed an
abolished NatA catalytic activity of NAA10 N101K-V5,
whereas the monomeric NAA10 catalytic activity appeared
unaffected (Fig. 2c). In contrast to NAA10 N101K-V5, a
portion of the NAA10 WT-V5 is complexed with NAA15
which exert little if any catalytic activity toward EEEI24
[14]. This could imply that the actual monomeric catalytic
activity is slightly higher for NAA10 WT-V5 than the
NAA10 N101K-V5 variant.
To understand why the NAA10 c.303C>A and c.303C>G
p.(N101K) variants hinder complex formation with
NAA15, a sequence- and structural analysis was conducted.
The multiple sequence alignment revealed that the Asn101
residue of NAA10 is not strictly conserved between ortho-
logues (Fig. 3a). However, all the amino acids in position 101
are small and uncharged which suggest that lysine with its
long, positively charged side chain is too dissimilar to be
tolerated. Interestingly, Asn101 is located in the NAA10 α3
helix which is part of the contact surface with NAA15 and the
side chain of Asn101 is protruding toward the NAA15 α12-
α13 loop (Fig. 3b). A previous study that delineated the
NAA10-NAA15 interactions of S. pombe NatA [13] reported
that the NAA10 α1-loop-α2 region forms the most intimate
interactions with NAA15, but the NAA10 α3 helix was also
found to make intermolecular interactions that supplements
the NAA10–NAA15 interface. It is plausible that the longer
side chain and positive charge of lysine can cause steric
hindrance/and or charge repulsion. Consequently, potentially
important intermolecular interactions mediated by Asn101
and/or other residues in the NAA10 α3 helix could be dis-
rupted and hinder optimal complex formation between
NAA10 and NAA15.
Altogether, the data indicate that the NAA10 c.303C>A
and c.303C>G p.(N101K) variants abolish NatA complex
formation and consequently also all NatA mediated N-
terminal acetylation on the ribosome. Monomeric NAA10 has
also been proposed to have NatA independent functions as a
KAT catalysing lysine acetylation as well as a noncatalytic
regulator of target substrates [2]. However, the NAA10 KAT
activity toward some substrates has been disputed due to a
lack of reproducibility [61]. The many cellular roles of
NAA10 corroborates the complexity and challenge of defin-
ing the molecular mechanisms underlying clinical manifes-
tations associated with NAA10 deficiency. In the case of
NAA10 c.303C>A and c.303C>G p.(N101K), the variants do
not seem to affect the monomeric functions of NAA10. Thus,
the girls' phenotypes are most likely mediated via impaired
NatA (NAA10-NAA15) Nt-acetylation activity, and not
KAT, NAT, or noncatalytic roles of monomeric NAA10.
Interestingly, the females harbouring the NAA10 c.303C>A
and c.303C>G p.(N101K) variants display hemihypertrophy,
which has not previously been described for any individuals
harbouring pathogenic NAA10 variants. Thus this may be one
such NatA-specific phenotype. In sum, NAA10 p.(N101K) is
the first variant reported to completely eradicate binding of
NAA15 and it may uniquely reflect the functional impact
of NatA.
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